Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects.

  title={Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects.},
  author={Thomas A Golper and Marsha Wolfson and S. Ahmad and Raimund Hirschberg and Paul S. Kurtin and L A Katz and R W Nicora and Donald Ashbrook and Joel D. Kopple},
  journal={Kidney international},
  volume={38 5},
Previous studies have reported conflicting results of carnitine supplementation on plasma lipids in patients with chronic renal failure. We therefore performed a four center, double-blind placebo controlled trial to evaluate the effects of post-hemodialysis intravenous injection of L-carnitine in ESRD patients on maintenance hemodialysis. Thirty-eight patients received up to six months of L-carnitine infusions (20 mg/kg) post-dialysis and 44 patients received placebo infusions. In both groups… 

Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review.

L-carnitine cannot be recommended for treating the dyslipidemia of maintenance hemodialysis patients and a promising effect of L-c Carnitine on anemia management is suggested.

Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease.

Long-term hemodialysis treatment is associated with a significant reduction in endogenous plasma and muscle L-c Carnitine levels and a significant increase in plasma acylcarnitines, while muscle levels continue to decline after 12 months of treatment.

Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients

Oral l-carnitine supplementation does not ameliorate the lipid profile in pediatric PD patients, but it causes a significant decrease in apolipoprotein B levels, Hence, carnitine supplements may be recommended for decreasing Apolipop Protein B levels in this patient population.

The effect of L-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients.

  • M. SuchitraV. Ashalatha P. Rao
  • Medicine, Biology
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • 2011
The present study demonstrates the significant benefit of L-Carnitine supplementation on inflammatory status in MHD patients as noted by marked decrease in hsCRP levels in comparison with the control group.

Effect of L-Carnitine on Amino Acid Metabolism in Elderly Patients Undergoing Regular Hemodialysis

L-C Carnitine increased the blood acylcarnitine levels, enhanced fatty acid metabolism, and affected AAs metabolism; this may be beneficial for energy production within the cardiac and skeletal muscles.

Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy.

It is shown that supplementation with carnitine and coenzyme Q10 could reduce serum levels of lipoprotein(a) in maintenance hemodialysis patients treated with statins.

Effect of carnitine supplementation on cardiac function in hemodialyzed children

3 months of L‐carnitine supplementation resulted in a significant increase in blood carnitine levels and the FC/AC ratio, but this was not associated with any significant improvement of cardiac function and no significant changes were observed in plasma triglycerides, total cholesterol or other lipoprotein parameters before or after carnitines supplementation.

Total carnitine and acylated carnitine ratio: relationship of free carnitine with lipid parameters in pediatric dialysis patients.

Elevated triglycerides were associated with elevated AC, suggesting carnitine insufficiency in pediatric patients on chronic PD or HD, and nutritional status, biochemical parameters, and fasting plasma lipoprotein concentrations were evaluated.



Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects.

Carnitine treatment was associated with a significant drop in pre-dialysis concentrations of serum urea nitrogen, creatinine and phosphorus, and no significant changes in any of these variables were noticed in the placebo group.

High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis.

A harmful effect of L-carnitine replacement therapy when given in high doses is suggested, causing aggravation of uremic hypertriglyceridemia and increased platelet aggregation in patients predisposed to thromboembolic phenomena.

Carnitine deficiency induced during hemodialysis and hyperlipidemia: effect of replacement therapy.

It is suggested that carnitine may be useful in treatment of hypertriglyceridemia and muscle Carnitine deficiency states induced during maintenance hemodialysis.

Ketogenic and antiketogenic effects of L-carnitine in hemodialysis patients.

The data suggest that low doses of L-carnitine are effective in treating hypertriglyceridemia in selected patients and avoids unphysiological high plasma levels of carn itine and carnitine esters and prevents antiketogenic effects in hemodialysis patients.

Carnitine depletion as a probable cause of hyperlipidemia in uremic patients on maintenance hemodialysis.

The results suggest that carnitine depletion induced by hemodialysis treatments has a probable causal relationship to hyperlipidemia in uremic patients on long-term maintenance hemodIALysis and that supplementation of carn itine or amino acids prevents carnitines depletion and improves hemodualysis hyper Lipidemia.

The effect of L-carnitine on lipid metabolism in patients on chronic haemodialysis.

Twenty-one patients on chronic haemodialysis were examined in a clinical controlled trial for the effect of carnitine on hyperlipoproteinaemia, and it was could not confirm the findings of others that Carnival produces lowering of serum triglycerides and increases of serum HDL-cholesterol.

A comparison of plasma and muscle carnitine levels in patients on peritoneal or hemodialysis for chronic renal failure.

It is postulate that the rapid decline in plasma levels of carnitine caused by hemodialysis initiates unilateral transport of the compound from muscle to the plasma, thus depleting the skeletal muscle stores of carnItine, and the plasma and muscle Carnival levels remained in the normal range in patients on intermittent peritoneal dialysis and CAPD.

Plasma lipoproteins, liver function and glucose metabolism in haemodialysis patients: lack of effect of L-carnitine supplementation.

The effects of L-carnitine administration (2 g i.v three times weekly for 6 weeks) were studied in a double blind trial comprising 2 X 14 patients on regular haemodialysis treatment and no effects of carnitine treatment on any of the variables could be detected.

Response patterns to DL-carnitine in patients on maintenance haemodialysis.

Two patterns of response to dl-carnitine could be distinguished: the 'paradoxic' response with a rise in serum triglyceride concentrations and the dual response to two different dosages of dl, which fell and the post-heparin fractional clearance rate of Intralipid increased significantly after all-c Carnage administration.

Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol.

It is suggested that L-carnitine can be effective in the management of hypertriglyceridemia in the hemodialyzed patient especially when low high-density lipoprotein-cholesterol levels are present.